

Sonali M Smith

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7130115/publications.pdf>

Version: 2024-02-01

177
papers

7,816
citations

81434

41
h-index

62345

84
g-index

181
all docs

181
docs citations

181
times ranked

8953
citing authors

#	ARTICLE	IF	CITATIONS
1	Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 88-94.	0.8	991
2	CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2018, 379, 1711-1721.	13.9	796
3	Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. <i>Blood</i> , 2003, 102, 43-52.	0.6	630
4	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
5	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	0.6	246
6	Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 3141-3149.	0.8	212
7	Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 3100-3109.	0.8	206
8	Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2015, 373, 1835-1844.	13.9	201
9	Temsirolimus Has Activity in Non-Mantle Cell Non-Hodgkin's Lymphoma Subtypes: The University of Chicago Phase II Consortium. <i>Journal of Clinical Oncology</i> , 2010, 28, 4740-4746.	0.8	181
10	Double hit and double expressors in lymphoma: Definition and treatment. <i>Cancer</i> , 2018, 124, 4622-4632.	2.0	121
11	Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1729-1736.	2.0	119
12	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	1.2	115
13	Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2484-2492.	0.8	106
14	Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. <i>Blood Advances</i> , 2017, 1, 715-727.	2.5	105
15	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
16	Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 3015-3022.	0.8	102
17	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	1.2	101
18	Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. <i>Journal of Clinical Oncology</i> , 2015, 33, 2399-2404.	0.8	97

#	ARTICLE	IF	CITATIONS
19	Continued Risk of Relapse Independent of Treatment Modality in Limited-Stage Diffuse Large B-Cell Lymphoma: Final and Long-Term Analysis of Southwest Oncology Group Study S8736. <i>Journal of Clinical Oncology</i> , 2016, 34, 2997-3004.	0.8	97
20	Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. <i>Blood</i> , 2018, 132, 2016-2025.	0.6	93
21	Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 356-364.e3.	0.2	88
22	PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell "inflamed" phenotype. <i>Blood</i> , 2019, 133, 2279-2290.	0.6	87
23	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	0.6	86
24	MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches. <i>Cancer</i> , 2014, 120, 3884-3895.	2.0	85
25	Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. <i>Lancet Haematology</i> , 2017, 4, e176-e182.	2.2	77
26	Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2015, 170, 445-456.	1.2	76
27	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	0.8	75
28	A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T-cell consortium trial. <i>British Journal of Haematology</i> , 2016, 172, 535-544.	1.2	71
29	Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus ¹³¹ I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. <i>Journal of Clinical Oncology</i> , 2018, 36, 697-703.	0.8	68
30	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	2.0	61
31	Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. <i>British Journal of Haematology</i> , 2018, 182, 916-920.	1.2	59
32	Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. <i>Cancer</i> , 2018, 124, 1733-1742.	2.0	58
33	The impact of MYC expression in lymphoma biology: Beyond Burkitt lymphoma. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 317-323.	0.6	57
34	Second Autologous Stem Cell Transplantation for Relapsed Lymphoma after a Prior Autologous Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 904-912.	2.0	56
35	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
36	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	0.6	56

#	ARTICLE	IF	CITATIONS
37	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
38	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. <i>Oncotarget</i> , 2016, 7, 4598-4610.	0.8	53
39	A prospective cohort study of patients with peripheral T-cell lymphoma in the United States. <i>Cancer</i> , 2017, 123, 1174-1183.	2.0	51
40	Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. <i>Blood</i> , 2022, 139, 413-423.	0.6	50
41	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1746-1753.	2.0	48
42	Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis. <i>Cancer</i> , 2018, 124, 136-144.	2.0	47
43	Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation. <i>JAMA Oncology</i> , 2019, 5, 715.	3.4	44
44	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39
45	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3 ^{hi} /dimCD4 ⁺ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <i>Modern Pathology</i> , 2016, 29, 1173-1182.	2.9	36
46	Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2019, 3, 2790-2799.	2.5	36
47	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study. <i>Blood</i> , 2019, 133, 1762-1765.	0.6	35
48	Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016. <i>Blood</i> , 2019, 133, 81-93.	0.6	34
49	A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520. <i>Leukemia and Lymphoma</i> , 2016, 57, 2359-2369.	0.6	33
50	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	1.8	29
51	Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 853-856.	2.0	28
52	Outcome of Lower-Intensity Allogeneic Transplantation in Non-Hodgkin Lymphoma after Autologous Transplantation Failure. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1255-1264.	2.0	27
53	The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). <i>Leukemia and Lymphoma</i> , 2013, 54, 1405-1410.	0.6	27
54	Outcomes of MYC-associated lymphomas after R-CHOP with and without consolidative autologous stem cell transplant: subset analysis of randomized trial intergroup SWOG S9704. <i>British Journal of Haematology</i> , 2016, 174, 686-691.	1.2	27

#	ARTICLE	IF	CITATIONS
55	Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 193-200.	0.2	27
56	Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. <i>Blood Advances</i> , 2018, 2, 933-940.	2.5	27
57	Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. <i>British Journal of Haematology</i> , 2008, 140, 313-319.	1.2	26
58	Highly clonal regulatory T-cell population in follicular lymphoma – inverse correlation with the diversity of CD8 ⁺ T cells. <i>Oncolmmunology</i> , 2015, 4, e1002728.	2.1	26
59	Targeting mTOR in mantle cell lymphoma: Current and future directions. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 175-183.	0.7	25
60	Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort. <i>Haematologica</i> , 2018, 103, e151-e153.	1.7	22
61	The Btk Inhibitor, PCI-32765, Induces Durable Responses with Minimal Toxicity In Patients with Relapsed/Refractory B-Cell Malignancies: Results From a Phase I Study. <i>Blood</i> , 2010, 116, 964-964.	0.6	22
62	ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. <i>Bone Marrow Transplantation</i> , 2021, 56, 2911-2921.	1.3	21
63	Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. <i>Journal of Hematology and Oncology</i> , 2017, 10, 117.	6.9	20
64	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq0 0 0 regBT / Overlock 10 Tf	2.2	20
65	Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 359-365.	2.0	20
66	Activity and tolerability of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7504-7504.	0.8	20
67	ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 302-313.	1.8	19
68	Understanding the New WHO Classification of Lymphoid Malignancies: Why It's Important and How It Will Affect Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 535-546.	1.8	19
69	Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. <i>Blood Advances</i> , 2019, 3, 3132-3135.	2.5	18
70	Hodgkin lymphoma arising in patients with chronic lymphocytic leukemia: outcomes from a large multi-center collaboration. <i>Haematologica</i> , 2021, 106, 2845-2852.	1.7	18
71	Dietary patterns and the risk of non-Hodgkin lymphoma. <i>Public Health Nutrition</i> , 2014, 17, 1531-1537.	1.1	17
72	Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. <i>Blood</i> , 2022, 139, 1147-1159.	0.6	17

#	ARTICLE	IF	CITATIONS
73	A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV+ lymphomas. <i>Leukemia and Lymphoma</i> , 2021, 62, 3493-3500.	0.6	17
74	Dissecting follicular lymphoma: high versus low risk. <i>Hematology American Society of Hematology Education Program</i> , 2013, 2013, 561-567.	0.9	16
75	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	0.9	16
76	Tandem Autologous Hematopoietic Cell Transplantation for Patients with Primary Progressive or Recurrent Hodgkin Lymphoma: A SWOG and Blood and Marrow Transplant Clinical Trials Network Phase II Trial (SWOG S0410/BMT CTN 0703). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 700-707.	2.0	16
77	An update in treating transformed lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 251-261.	0.7	16
78	Phase 1 study of lenalidomide plus dose-adjusted EPOCH in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2. <i>Cancer</i> , 2019, 125, 1830-1836.	2.0	16
79	Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas. <i>Haematologica</i> , 2022, 107, 1608-1618.	1.7	16
80	Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL). <i>Journal of Clinical Oncology</i> , 2018, 36, 7549-7549.	0.8	15
81	Alterations of 5-hydroxymethylation in circulating cell-free DNA reflect molecular distinctions of subtypes of non-Hodgkin lymphoma. <i>Npj Genomic Medicine</i> , 2021, 6, 11.	1.7	13
82	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. <i>Blood</i> , 2019, 134, 349-349.	0.6	13
83	Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. <i>Blood Cancer Journal</i> , 2019, 9, 97.	2.8	11
84	Clinical Predictors of Transplant Related Mortality after Reduced Intensity Allogeneic Stem Cell Transplantation (RIST). <i>Blood</i> , 2004, 104, 1145-1145.	0.6	11
85	Management of relapsed diffuse large B-cell lymphoma. <i>Current Oncology Reports</i> , 2008, 10, 393-403.	1.8	10
86	Personalized Treatment of Lymphoma: Promise and Reality. <i>Seminars in Oncology</i> , 2011, 38, 225-235.	0.8	10
87	Recommendations and outcomes from a geriatric assessment guided multidisciplinary clinic prior to autologous stem cell transplant in older patients. <i>Journal of Geriatric Oncology</i> , 2021, 12, 585-591.	0.5	10
88	Association Of Graft Vs. Host Disease (GVHD) With a Lower Relapse/Progression Rate After Allogeneic Hemopoietic Stem Cell Transplantation (HSCT) With Reduced Intensity Conditioning In Patients With Follicular and Mantle Cell Lymphoma: A Cibmtr Analysis. <i>Blood</i> , 2013, 122, 2093-2093.	0.6	10
89	Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: Results of CALGB 59906. <i>Leukemia and Lymphoma</i> , 2006, 47, 1511-1517.	0.6	9
90	Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 78-85.	2.0	9

#	ARTICLE	IF	CITATIONS
91	Work-Life Balance Solutions for Physicians—It's All About You, Your Work, and Others. <i>Mayo Clinic Proceedings</i> , 2019, 94, 573-576.	1.4	9
92	CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. <i>Blood</i> , 2020, 136, 27-28.	0.6	9
93	Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study. <i>Blood</i> , 2009, 114, 933-933.	0.6	9
94	Sequential Brentuximab Vedotin (Bv) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study. <i>Blood</i> , 2017, 130, 733-733.	0.6	9
95	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	0.6	9
96	Evolution of therapy for limited stage diffuse large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2022, 12, 33.	2.8	9
97	A phase 2 study of epcotilone B analog BMS-247550 (NSC 710428) in patients with relapsed aggressive non-Hodgkin lymphomas. <i>Cancer</i> , 2013, 119, 1683-1689.	2.0	8
98	A Phase III Study Of Enzastaurin In Patients With High-Risk Diffuse Large B Cell Lymphoma Following Response To Primary Treatment: The Prelude Trial. <i>Blood</i> , 2013, 122, 371-371.	0.6	8
99	Integrative Immunogenomic Characterization of Diffuse Large B-Cell Lymphoma (DLBCL) Identifies Four Molecular Subtypes with Distinct Immune Landscapes. <i>Blood</i> , 2019, 134, 924-924.	0.6	8
100	Selective enhancement of ifosfamide-induced toxicity in Chinese hamster ovary cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 291-302.	1.1	7
101	A systematic review of comparative schedule-related toxicities with maintenance rituximab in follicular and mantle cell lymphomas. <i>Leukemia and Lymphoma</i> , 2014, 55, 1288-1294.	0.6	7
102	American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 720-728.	0.6	7
103	Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	7
104	Irreversible myelosuppression after fludarabine-melphalan conditioning: observations in patients with graft rejection. <i>Blood</i> , 2004, 103, 4373-4374.	0.6	6
105	Surveillance Imaging in Patients in Remission From Hodgkin and Diffuse Large B-Cell Lymphoma. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 2115.	3.8	6
106	Romidepsin and total skin electron beam therapy in advanced stage mycosis fungoides and S�azary syndrome. <i>British Journal of Haematology</i> , 2019, 186, 377-379.	1.2	6
107	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
108	Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab. <i>Blood</i> , 2013, 122, 247-247.	0.6	6

#	ARTICLE	IF	CITATIONS
109	The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2018, 36, 7511-7511.	0.8	6
110	Alternative Donor Transplantation For Adults With Lymphoma: Comparison Of Umbilical Cord Blood Versus 8/8 HLA-Matched Donor (URD) Versus 7/8 URD. Blood, 2013, 122, 161-161.	0.6	6
111	CHOP Plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term benefits: A Case Report and Literature Review. Journal of Gastrointestinal Cancer, 2007, 38, 59-62.	0.6	5
112	Anti-Bcl2 therapy in chronic myelogenous leukemia. Leukemia and Lymphoma, 2008, 49, 1232-1233.	0.6	5
113	Effect of time to relapse on overall survival in patients with mantle cell lymphoma following autologous haematopoietic cell transplantation. British Journal of Haematology, 2021, 195, 757-763.	1.2	5
114	A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas. Blood, 2019, 134, 351-351.	0.6	5
115	Prospective Phase I Multi-Center Trial Incorporating Lenalidomide (LEN) into Dose-Adjusted EPOCH Plus Rituximab (DA-EPOCH-R) in Patients with Double Hit (DHL) or Double Expressing (DEL) Lymphomas: Final Results. Blood, 2016, 128, 4191-4191.	0.6	5
116	Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 91-97.	0.2	4
117	University of Chicago phase II consortium trial of selumetinib (<scp>MEK</scp>i) demonstrates low tolerability and efficacy in relapsed DLBCL. British Journal of Haematology, 2018, 181, 264-267.	1.2	4
118	Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma. Blood, 2021, 137, 3454-3459.	0.6	4
119	Reduced-intensity transplantation for lymphoma. Current Treatment Options in Oncology, 2006, 7, 295-305.	1.3	3
120	Clinical and Biological Prognostic Factors in Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 647-662.	0.9	3
121	R-CHOP Versus R-Bendamustine with or without Rituximab Maintenance in Newly Diagnosed Follicular Lymphoma Patients with High SUV at Baseline PET. Blood, 2020, 136, 39-40.	0.6	3
122	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ,,¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. Blood, 2006, 108, 2483-2483.	0.6	3
123	New drugs for the treatment of non-Hodgkin lymphomas. Chinese Clinical Oncology, 2015, 4, 14.	0.4	3
124	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. Blood, 2021, 138, 3528-3528.	0.6	3
125	Indolent lymphomas: introduction to a series highlighting progress and ongoing challenges. Haematologica, 2022, 107, 4-6.	1.7	3
126	Nonmyeloablative transplantation for lymphoma. Current Treatment Options in Oncology, 2003, 4, 261-268.	1.3	2

#	ARTICLE	IF	CITATIONS
127	CHOP plus Alemtuzumab can Induce Metabolic Response by FDG-PET but has Minimal Long-term Benefits: A Case Report and Literature Review. <i>Journal of Gastrointestinal Cancer</i> , 2007, 38, 19-23.	0.6	2
128	Old versus frail: why it matters in lymphoma. <i>Leukemia and Lymphoma</i> , 2011, 52, 938-940.	0.6	2
129	Prognosis in diffuse large B-cell lymphoma. <i>Cancer</i> , 2013, 119, 1129-1131.	2.0	2
130	Toward a global understanding of lymphoma: epidemiologic clues from the second most populous country. <i>Leukemia and Lymphoma</i> , 2013, 54, 901-902.	0.6	2
131	Treatment of aggressive B-cell lymphomas. <i>Hematological Oncology</i> , 2017, 35, 84-87.	0.8	2
132	Pembrolizumab and Copanlisib for the Treatment of Relapsed or Refractory Mature T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 4031-4031.	0.6	2
133	Beyond PD-1: Investigating the Therapeutic Potential of TIGIT Blockade in DLBCL. <i>Blood</i> , 2019, 134, 391-391.	0.6	2
134	Prospective Study of Immunomodulation with GM-CSF, IL-2, and Rituximab Following Autologous Stem Cell Transplant (SCT) in Patients with Relapsed Lymphomas.. <i>Blood</i> , 2004, 104, 918-918.	0.6	2
135	A Phase II Study Of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) Alternating With Pralatrexate (P) As Front Line Therapy For Patients With Peripheral T-Cell Lymphoma (PTCL): Preliminary Results From The T- Cell Consortium Trial. <i>Blood</i> , 2013, 122, 3044-3044.	0.6	2
136	Phase II Study of Temsirrolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas: Final Analysis of NCI 8309. <i>Blood</i> , 2016, 128, 4147-4147.	0.6	2
137	Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or matched unrelated donor (MUD) reduced intensity conditioning (RIC) HCT for diffuse large b-cell lymphoma (DLBCL): A CIBMTR and EBMT analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7056-7056.	0.8	2
138	Multicenter Analysis of 150 Very Elderly Non-Hodgkin's Lymphoma (NHL) Patients: Impact of Comorbidities and Response to Initial Therapy on Survival. <i>Blood</i> , 2010, 116, 3124-3124.	0.6	2
139	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). <i>Blood</i> , 2021, 138, 1349-1349.	0.6	2
140	Extranodal Presentation in Limited Stage DLBCL As a Prognostic Marker in Three Sequential SWOG Trials S0014, S0313 and S1001 (NCT00005089, NCT00070018, NCT01359592). <i>Blood</i> , 2021, 138, 1423-1423.	0.6	2
141	Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816. <i>Leukemia and Lymphoma</i> , 2020, 61, 2442-2447.	0.6	1
142	Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah's Witnesses. <i>Leukemia and Lymphoma</i> , 2021, 62, 1497-1501.	0.6	1
143	Fludarabine Melphalan and Alemtuzumab (Campath) Conditioning for Pts with High Risk Myeloid Malignancies. High Cure Rate for Pts with Low Leukemia Burden.. <i>Blood</i> , 2004, 104, 2321-2321.	0.6	1
144	Sequential Topoisomerase I (Topo I) and Topoisomerase II (Topo II) Inhibitors in Relapsed/Refractory Aggressive NHL: Results of CALGN 59906, a Phase II Study of Doxorubicin and Topotecan.. <i>Blood</i> , 2004, 104, 2500-2500.	0.6	1

#	ARTICLE	IF	CITATIONS
145	Leukemic Relapse after Allogeneic Stem Cell Transplantation with a T-Cell Depleted Reduced Intensity Conditioning (RIST) Regimen.. Blood, 2005, 106, 2022-2022.	0.6	1
146	Phase II study of the PD1-inhibitor pembrolizumab for the treatment of relapsed or refractory mature t-cell lymphoma.. Journal of Clinical Oncology, 2018, 36, 7568-7568.	0.8	1
147	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
148	Prognostication of older Hodgkin lymphoma (HL) patients (pts): Findings from a multicenter phase II study.. Journal of Clinical Oncology, 2018, 36, 7540-7540.	0.8	1
149	Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience. Clinical Lymphoma, Myeloma and Leukemia, 2021, , .	0.2	1
150	Phase I/II Clinical Trial of Temsirolimus and Lenalidomide in Patients with Relapsed and Refractory Lymphomas. Blood, 2020, 136, 43-44.	0.6	1
151	DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?. Clinical Advances in Hematology and Oncology, 2021, 19, 698-709.	0.3	1
152	Maintenance rituximab revisited: is it worth the cost?. Leukemia and Lymphoma, 2012, 53, 2331-2332.	0.6	0
153	Hematopoietic Stem Cell Transplantation in Nodal T Cell Non-Hodgkin Lymphomas: Revisiting the Issues. Biology of Blood and Marrow Transplantation, 2015, 21, 777-779.	2.0	0
154	Too much and not enough: revisiting maintenance rituximab in indolent lymphomas. Haematologica, 2022, 107, 353-354.	1.7	0
155	New Cytogenetic Abnormalities Are Frequent in AML and MDS Relapsing after Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2006, 108, 3675-3675.	0.6	0
156	What Is the Best Strategy for Incorporating New Agents into the Current Treatment of Follicular Lymphoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 481-487.	1.8	0
157	The Influence Of Lifestyle Factors On Tumor-Related Markers and The Microenvironment In Follicular Lymphoma (FL): Novel Interactions and Collective Impact On Survival. Blood, 2013, 122, 1762-1762.	0.6	0
158	Single Agent Ofatumumab In Patients With Relapsed and/Or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results From a Phase II Open Label Study. Blood, 2013, 122, 5131-5131.	0.6	0
159	Selective MEK Inhibition with AZD-6244 (selumetinib) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A University of Chicago Phase II Consortium Trial. Blood, 2015, 126, 3990-3990.	0.6	0
160	Clonal Evolution Pattern of Leukemia Progression and Richter Transformation in Ibrutinib-Relapsed CLL Patients. Blood, 2016, 128, 3961-3961.	0.6	0
161	<i>Pd-1</i> gene alterations to identify a subset of diffuse large B cell lymphoma that harbor a T cell inflamed phenotype.. Journal of Clinical Oncology, 2018, 36, 7566-7566.	0.8	0
162	Characterization of the immunogenomic landscape of follicular lymphoma.. Journal of Clinical Oncology, 2018, 36, e19531-e19531.	0.8	0

#	ARTICLE	IF	CITATIONS
163	A Multi-Center Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Fimepinostat (CUDC-907) in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Lymphoma. <i>Blood</i> , 2019, 134, 4104-4104.	0.6	0
164	Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016. <i>Blood</i> , 2019, 134, 2771-2771.	0.6	0
165	Transformed Follicular Lymphoma. , 2020, , 135-163.		0
166	Reply to E. Hawkes et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 4222-4223.	0.8	0
167	S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements. <i>Blood</i> . 2021. 138. 3565-3565.	0.6	0
168	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. <i>Blood</i> , 2021, 138, 2425-2425.	0.6	0
169	A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma. <i>Blood</i> , 2021, 138, 2420-2420.	0.6	0
170	Utility Estimation of Rituximab Versus Bendamustine-Rituximab Induction in Indolent Non-Hodgkin Lymphomas Using Patient-Reported Quality of Life Survey Data. <i>Blood</i> , 2021, 138, 4013-4013.	0.6	0
171	Outcomes of Histological Variants of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL): A Single-Center Retrospective Study. <i>Blood</i> , 2021, 138, 4548-4548.	0.6	0
172	Selinexor Efficacy and Safety Are Independent of Renal Function in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis from the Pivotal Phase 2b Sadal Study. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
173	Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era. <i>Blood</i> , 2020, 136, 24-26.	0.6	0
174	Single-Cell Analysis of the Classical Hodgkin Lymphoma Immune Environment Reveals a Clonally-Expanded CD8+ T Cell Population with a Cytotoxic Phenotype. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
175	EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort. <i>Blood</i> , 2020, 136, 4-6.	0.6	0
176	Effect of Age on the Efficacy and Safety of Single Agent Oral Selinexor in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): A Post-Hoc Analysis of the Sadal Pivotal Study. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
177	Something old, something new. <i>Leukemia and Lymphoma</i> , 2006, 47, 576-7.	0.6	0